339539-06-9

Upstream product

• 6342-70-7 3-methoxymethylsalicylate 
• 1972-28-7 diethylazodicarboxylate 
• 100-39-0 benzyl bromide 

Downstream Products

• 52508-44-8 2-benzyloxy-3-hydroxymethyl-1-methoxybenzene 
• 33038-10-7 7-methoxy-3-methyl-1-benzofuran 
• 33051-29-5 2-(2-acetyl-6-methoxyphenoxy)acetic acid 
• 33051-28-4 ethyl 2-(2-acetyl-6-methoxyphenoxy)acetate 
• 703-98-0 1-(2-hydroxy-3-methoxyphenyl)ethanone 
• 87307-77-5 1-<3-methoxy-2-(phenylmethoxy)phenyl>ethanone 
• 23806-76-0 2-(benzyloxy)-3-methoxybenzoic acid 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Expeditious synthesis of benzopyrans via lewis acid-catalyzed C-H functionalization: Remarkable enhancement of reactivity by an ortho substituent

An expeditious construction of a benzopyran skeleton via Lewis acid-catalyzed C-H functionalization was achieved. In this process, a [1,5] hydride shift and 6-endo cyclization successively occurred to give benzopyrans. The presence of substituents ortho to the alkoxy group significantly enhanced the reactivity, affording the desired compounds in excellent chemical yields with short reaction times.

7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B

This invention relates to compounds of Formula I that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.